Highland Capital Management (Texas)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-37,110
| Closed | -$1.71M | – | 317 |
|
|
2017
Q2 | $1.71M | Sell |
37,110
-25,890
| -41% | -$1.19M | 0.07% | 149 |
|
|
2017
Q1 | $2.73M | Buy |
+63,000
| New | +$2.73M | 0.14% | 118 |
|
|
2016
Q4 | – | Sell |
-92,257
| Closed | -$4.67M | – | 312 |
|
|
2016
Q3 | $4.67M | Buy |
92,257
+15,700
| +21% | +$795K | 0.14% | 108 |
|
|
2016
Q2 | $3.48M | Sell |
76,557
-58,443
| -43% | -$2.66M | 0.14% | 112 |
|
|
2016
Q1 | $5.34M | Buy |
135,000
+98,502
| +270% | +$3.9M | 0.24% | 102 |
|
|
2015
Q4 | $2.07M | Sell |
36,498
-134,902
| -79% | -$7.63M | 0.07% | 152 |
|
|
2015
Q3 | $6.82M | Sell |
171,400
-34,600
| -17% | -$1.38M | 0.2% | 114 |
|
|
2015
Q2 | $9.84M | Buy |
206,000
+76,000
| +58% | +$3.63M | 0.2% | 107 |
|
|
2015
Q1 | $5.16M | Buy |
+130,000
| New | +$5.16M | 0.11% | 131 |
|
|
2014
Q2 | – | Sell |
-80,000
| Closed | -$1.29M | – | 286 |
|
|
2014
Q1 | $1.29M | Buy |
+80,000
| New | +$1.29M | 0.05% | 144 |
|